Prices are updated after-hours

Pharmaceutical preparation manufacturing

KemPharm Inc

KMPH | $5.46 6.04% 0

|

(0.0% 1d) (0.7% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea treatment profitable

add to watch list Paper trade email alert is off

Oasmia Pharmaceutical AB

OASMY | $0.02 4650.0% 200

|

(0.0% 1d) (0.0% 1m) (6566.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-57.98% volume)
Earnings Calendar:
Market Cap: $ 3,586,956
http://www.oasmia.se/
Sec Filling | Patents | 28 employees

(SE) oasmia pharmaceutical ab develops a new generation of drugs within human and veterinary oncology. the product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. the product development is based on in-house research within nanotechnology and company patents.

profitable education

add to watch list Paper trade email alert is off

Bright Minds Biosciences Inc

DRUG | $1.25 -6.61% 11K

|

(0.0% 1d) (-4.8% 1m) (-62.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-81.0% volume)
Earnings Calendar:
Market Cap: $ 5,542,296
https://brightmindsbio.com
Sec Filling | Patents | 908 employees

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

treatment

add to watch list Paper trade email alert is off

AngioGenex, Inc.

AGGX | $0.0002

|

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (19900.0% volume)
Earnings Calendar:
Market Cap: $ 6,310

Sec Filling | Patents | 2 employees

add to watch list Paper trade email alert is off

CalEthos, Inc.

BUUZ 4 | $2.62 0% 3

|

(0.0% 1d) (0.0% 1m) (424.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.0% volume)
Earnings Calendar:
Market Cap: $ 66,366,015

Sec Filling | Patents | 1 employees

(US) calethos, inc. does not have significant operations. it intends to seek, investigate and, acquire an interest in business opportunities in the california cannabis industry. previously, it was involved in the acquisition, management, and holding of multi-family properties in the united states. the company was formerly known as realsource residential, inc. changed its name to calethos, inc. in december 2018. calethos, inc. is based in tustin, california. as of september 12, 2018, calethos, inc. operates as a subsidiary of m1 advisors, llc.

add to watch list Paper trade email alert is off

INTEGRATED BIOPHARMA INC

INBP 4 | $0.215 116.3% 600

|

(0.0% 1d) (-6.4% 1m) (-41.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (59900.0% volume)
Earnings Calendar:
Market Cap: $ 6,471,416

Sec Filling | Patents | 143 employees

integrated biopharma inc is a pharmaceuticals company based out of 225 long avenue, hillside, new jersey, united states.

add to watch list Paper trade email alert is off

China Health Industries Holdings, Inc.

CHHE | $0.39 592.31% 1.2K

|

(0.0% 1d) (0.0% 1m) (144.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (839.2% volume)
Earnings Calendar:
Market Cap: $ 25,560,497

Sec Filling | Patents | 96 employees

add to watch list Paper trade email alert is off

REGENERX BIOPHARMACEUTICALS INC

RGRX 4 | $0.0012 2191.67% 420

|

(0.0% 1d) (0.0% 1m) (-97.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-28.31% volume)
Earnings Calendar:
Market Cap: $ 181,031

Sec Filling | Patents | 3 employees

regenerx is a publicly traded, clinical-stage, biopharmaceutical company focused on tissue protection, repair and regeneration. regenerx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. regenerx’s management team is focused on moving three distinct tβ4-based drug candidates through the clinic: rgn-137, rgn-259 and rgn-352. regenerx also holds over 75 issued patents or patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. currently, regenerx has active partnerships in three major territories: the u.s. and canada, china, and pan asia. our partners have been moving forward and making significant progress in each territory with rgn-259, our ophthalmic drug candidate, and are preparing to initiate their clinical trials programs. in each case, the cost of development is being borne by our partners with no financial ob

add to watch list Paper trade email alert is off

MusclePharm Corp

MSLP | $0.0002

|

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (406.28% volume)
Earnings Calendar:
Market Cap: $ 6,677

Sec Filling | Patents | 27 employees

add to watch list Paper trade email alert is off

GENEREX BIOTECHNOLOGY CORP

GNBT | $0.0006

|

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-86.57% volume)
Earnings Calendar:
Market Cap: $ 73,235
http://www.generex.com/
Sec Filling | Patents | 14 employees

(US)

add to watch list Paper trade email alert is off

Kyto Technology & Life Science, Inc.

KBPH | $1.0

|

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.0% volume)
Earnings Calendar:
Market Cap: $ 5,836,828

Sec Filling | Patents | 3 employees

kyto technology and life science, inc., formerly kyto biopharma, inc., seeks to develop a specialized vehicle for early stage technology and life science companies. the company operates as a mentor, advisor, external manager and investor for selected privately held companies in the united states of america, canada and israel. the company's portfolio includes cnote group, inc. (cnote), exodos/achelios therapeutics, inc. (achelios), seal rock therapeutics, inc., and crater, llc (crater). cnote provides an alternative savings product that pays up to 35x the interest of a traditional savings account. crater provides the surveybot software program, which enables video chat between a moving company's representative and the customer. achelios is a specialty pharmaceutical company with primary focus on new therapeutic entity (nte) development for the treatment of pain and inflammation by delivered medications.

add to watch list Paper trade email alert is off

SANGUI BIOTECH INTERNATIONAL INC

SGBI | $0.0015 700.0% 200K

|

(0.0% 1d) (0.0% 1m) (-72.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1146.8% volume)
Earnings Calendar:
Market Cap: $ 314,933
http://www.sanguibiotech.com/
Sec Filling | Patents | n/a employees

(DE)

add to watch list Paper trade email alert is off

PROCYON CORP

PCYN 4 | $0.298 57.72% 5K

|

(0.0% 1d) (0.0% 1m) (-5.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-46.81% volume)
Earnings Calendar:
Market Cap: $ 2,416,300

Sec Filling | Patents | 19 employees

procyon corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the united states. the company offers advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions under the amerigel brand name. it also provides bioactive collagen products under the helix3 brand name. in addition, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products; wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the amerx brand name; and compression garment line products under the extremit-ease name. it sells its products through distributors to institutio

add to watch list Paper trade email alert is off

METROSPACES, INC.

MSPC | $0.0001 0.0% 1.5K

|

(0.0% 1d) (-99.0% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.58% volume)
Earnings Calendar:
Market Cap: $ 3,041,512

Sec Filling | Patents | 3 employees

(US) metrospaces is a proptech company, combining world-class real estate development with cutting-edge technology. our distinctive focus on leveraging novel technology in this space forges a uniquely valuable, transformative business.

add to watch list Paper trade email alert is off

IMMUNE PHARMACEUTICALS INC

IMNPQ | $0.001

|

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-93.85% volume)
Earnings Calendar:
Market Cap: $ 181,895

Sec Filling | Patents | 6 employees

(US)

add to watch list Paper trade email alert is off

UMeWorld Ltd

UMEWF | $0.48 0% 500

|

(0.0% 1d) (0.0% 1m) (199.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2143.13% volume)
Earnings Calendar:
Market Cap: $ 52,581,730

Sec Filling | Patents | 2 employees

umeworld limited, a holding company, operates as an educational technology company with a focus on the k-12 education market in china. the company's k-12 flagship product is umfun, a cloud-based assessment and learning analytics platform that analyzes and adapts to a student's performance and personalizes the delivery of proprietary educational items in accordance with the student's learning needs. the company's platform provides standards-based instruction, practice, assessments, and productivity tools that enhance the performance of educators and students. its products also enable educators to track student performance in real-time to address individual student learning gaps, while allowing administrators to monitor student progress and measure teacher effectiveness. umeworld limited serves schools, teachers, students, and parents through online and mobile platforms. the company was formerly known as alpharx, inc. and changed its name to umeworld limited in march 2013. umeworld has a

education

add to watch list Paper trade email alert is off

ACURA PHARMACEUTICALS, INC

ACUR 4 | $0.0042 2285.71% 1.6K

|

(0.0% 1d) (0.0% 1m) (-93.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (125.0% volume)
Earnings Calendar:
Market Cap: $ 278,667
http://acurapharm.com/
Sec Filling | Patents | 13 employees

(US) acura pharmaceuticals, inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. we have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • limitx™ technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. in 2014, we were awarded a $300,000 grant from the national institute on drug abuse to advance early stage development of our limitx technology. • aversion® technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features to discourage common methods of pharmaceutical product misuse and abuse while providing effective pain relief. oxaydo® tablets (oxycodone hcl, cii), is the first approved product using aversion® in the united states. on january 7, 2015, we entered int

add to watch list Paper trade email alert is off

SUNWIN STEVIA INTERNATIONAL, INC.

SUWN | $0.0003 3900.0% 81K

|

(0.0% 1d) (0.0% 1m) (-96.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40436.0% volume)
Earnings Calendar:
Market Cap: $ 59,890
http://sunwininternational.com
Sec Filling | Patents | 249 employees

(China (Mainland)) sunwin stevia international, inc. (“sunwin”) is an integrated global agricultural processing firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. sunwin is engaged in the manufacture and sale of a wide range of neutraceutical products. our product lines include zero-calorie all natural stevia sweeteners and traditional chinese medicines prepared from 100% organic herbal ingredients. sunwin operates in china through its wholly owned subsidiary, shangdong qufu natural green engineering co., ltd. which was established in 1996. sunwin operates in north america through its wholly owned subsidiary sunwin stevia international corp. usa.

add to watch list Paper trade email alert is off

Wellness Center USA, Inc.

WCUI | $0.0006 800.0% 350

|

(0.0% 1d) (0.0% 1m) (-94.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-99.33% volume)
Earnings Calendar:
Market Cap: $ 78,376

Sec Filling | Patents | 8 employees

wellness center usa, inc. (www.wellnesscenterusa.com) is a hybrid healthcare company that combines best in class technologies, software, devices, providers, protocols, goods, and services. it was created to address important healthcare and wellness needs via breakthrough solutions, all centered around the "well-being of the body and mind". wellness center usa, inc. is the parent company of three businesses reporting consolidated: stealth mark, national pain centers, and psoria-shield.

add to watch list Paper trade email alert is off

Immune Therapeutics, Inc.

IMUN | $0.093 214.52% 1.8K

|

(0.0% 1d) (0.0% 1m) (-84.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (52.37% volume)
Earnings Calendar:
Market Cap: $ 7,780,180
https://www.immunetherapeutics.com/
Sec Filling | Patents | 2 employees

(US) immune therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of our novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. company’s technology platform is built on two different immunotherapies, low dose naltrexone (ldn) and methionine-enkephalin (menk). both therapies have been decades in the making at institutions such as the pennsylvania state university medical school at hershey, university of chicago, state university of new york, and multiple sclerosis center at ucsf.

add to watch list Paper trade email alert is off

← Previous
1
2
3
4
5
6
Next →

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

77%

23%

Top 10 Gainers

AGBA | News | $1.22 205.0% 86M

|

EGOX | $0.054 50.0% 290M

|

CHRO | $1.66 35.51% 70K

|

INDO | $5.43 33.09% 10M

|

Energy Minerals

NVFY | $2.71 28.44% 31M

|

Consumer Durables

ZCMD | $1.86 28.28% 29M

|

Commercial Services

RWOD | $10.08 26.05% 5.6M

|

HUSA 4 | $2.07 23.95% 2.1M

|

Energy Minerals

TPET | $0.4001 22.02% 35M

|

SRFM 4 | $0.6 21.29% 850K

|

Last 48 Hours Insiders Buying

CLSD | $1.42 7.58% 130K

|

Health Technology

| 14:00
CDZI P 25000 | $2.275 1.11% 74K

|

| 14:00
ETST P 39000 | $0.068 43K

|

| 13:30
FNLC P 1275 | $22.62 2.08% 8K

|

| 12:30
ADMQ | $0.0532 480K

|

| 10:30
AXR P 2400 | $22.26 0.41% 180

|

| 21:00
QCRH P 118 | $56.105 1.25% 11K

|

| 18:01
VUZI P 7500 | $1.245 -1.19% 140K

|

Electronic Technology

| 18:00
RMCF | $3.5501 390

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar